Key facts
- This page summarizes Bronwen Bastone's Form 4 filing for Enfusion, Inc..
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 21 Apr 2025, 17:01.
Bronwen Bastone - 21 Apr 2025 Form 4 Insider Report for Enfusion, Inc.
- Reporting relationship
- Chief People Officer
- Issuer ticker
- N/A
- Reported as of
- 21 Apr 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Apr 2025, 17:01:38 UTC
- Prior SEC filing
- 07 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew Campobasso, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Bronwen Bastone filed Form 4 for Enfusion, Inc. on 21 Apr 2025.
Change
- Previous filing in this sequence was filed on 07 Mar 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ENFN
transaction
Class A Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -15,864
- Change %
- -7.4%
- Price
- Shares after
- 197,187
- Date
- 21 Apr 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F3, F4
ENFN
transaction
Class A Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -161,893
- Change %
- -82%
- Price
- Shares after
- 35,294
- Date
- 21 Apr 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F5
ENFN
transaction
Class A Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -35,294
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 21 Apr 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F6, F7
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ENFN
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -10,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 21 Apr 2025
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 10,000
- Exercise price
- $9.86
- Footnotes
- F1, F7, F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Bronwen Bastone is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 8 footnotes
Footnote F1
Disposed of pursuant to the Agreement and Plan of Merger, dated as of January 10, 2025 (the "Merger Agreement"), by and among Clearwater Analytics Holdings, Inc. (the "Parent"), Poseidon Acquirer, Inc., a direct, wholly-owned subsidiary of the Parent, Poseidon Merger Sub I, Inc., a wholly-owned subsidiary of the Parent, Poseidon Merger Sub II, LLC, an indirect subsidiary of the Parent, Enfusion, Inc. ("Enfusion"), and Enfusion Ltd. LLC, a subsidiary of Enfusion.
Footnote F2
Under the terms of the Merger Agreement, each eligible share of Enfusion's Class A common stock, par value $0.001 per share (the "Common Stock"), issued and outstanding was converted into the right to receive, at the election of the holder of such share of Common Stock, and subject to proration in accordance with the Merger Agreement: (i) cash in an amount equal to $5.85 and (ii) a number of shares of Class A common stock of the Parent, par value $0.001 per share (the "Parent Common Stock") equal to the Per Share Parent Stock Amount (as defined in the Merger Agreement) (the "Per Share Mixed Consideration"); (ii) a number of shares of Parent Common Stock equal to the Exchange Ratio (the "Per Share Stock Consideration"); or (iii) cash in an amount equal to the Aggregate Consideration Per Share (as defined in the Merger Agreement) (the "Per Share Cash Consideration").
Footnote F3
Represents (i) shares of Common Stock, which were converted into the right to receive the merger consideration, at the election of the holder of such share of Common Stock; and (ii) shares underlying restricted stock units ("RSUs") of Enfusion, which were converted into Parent RSUs equal to the product of (a) the number of shares of Common Stock subject to each Enfusion RSU multiplied by (b) the Exchange Ratio.
Footnote F4
Due to an inadvertent administrative error the amount of securities beneficially owned previously reported was overstated by 8,824 shares.
Footnote F5
Represents shares of Common Stock underlying unvested RSUs of Enfusion, which were converted into Parent RSUs equal to the product of (a) the number of shares of Common Stock subject to each Enfusion RSU multiplied by (b) the Exchange Ratio.
Footnote F6
Represents shares of Common Stock underlying performance stock units, which were cancelled for no consideration.
Footnote F7
As a result of the consummation of the transactions contemplated Merger Agreement, the Reporting Person ceased to be the beneficial owner of any securities of Enfusion. This Form 4 constitutes an exit filing by the Reporting Person.
Footnote F8
Under the terms of the Merger Agreement, each option to purchase shares of Common Stock with a per share exercise price that is less than the Per Share Cash Consideration (an "In-the-Money Option"), whether vested or unvested, was cancelled in exchange for the right of the holder to receive an amount in cash equal to the product of (i) the number of shares of Common Stock subject to such In-the-Money Option, multiplied by (ii) the excess of the Per Share Cash Consideration over the exercise price of such In-the-Money Option, less applicable tax withholding.